ITGAM and neoplasm: Finally, ICI + anti-Gr-1 treatment did not decrease the frequencies of CD11b+Ly-6G+ or CD11b+Ly-6C+ expressing cells in tumours (Fig. 2f,g), non-tumoural kidney, spleen, bone marrow and blood (data not shown), revealing that the attempted depletion of these myeloid cells was not successful, likely due to the rapid adaptation of myelopoiesis and the possible formation of neutralising antibodies against the foreign immunodepleting antibody in this immune competent model after long term and repeated administration of the anti-Gr-1 antibody.